← Landscape

Trial NCT07039916

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Phase
Phase 3
Sponsor
Immunovant Sciences GmbH
Conditions
Generalized Myasthenia Gravis
Ages
18–80 years
View on ClinicalTrials.gov ↗

Eligibility criteria

Highlighted: restrictions our model extracted, each a verbatim quote (pink = excludes outright, blue = only under conditions).

Inclusion Criteria: * Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures. * Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit * Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1) Additional inclusion criteria are defined in the protocol. Exclusion Criteria: * Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit. * Have had a thymectomy performed < 6 months prior to the Screening Visit or have a planned thymectomy during the study * Have any active or untreated malignant thymomaPrior malignancy Additional exclusion criteria are defined in the protocol.

Restrictions found (1)

Recruiting in Massachusetts

  • Site Number - 1049 · Foxborough, Norfolk County